Interstitial lung disease (ILD) is a chronic progressive disease that dramatically impacts your lung health and function. Depending on the severity of your symptoms, your medical team will tailor your treatment options to slow disease progression and provide as much comfort as possible.
We make it easy for you to participate in a clinical trial for Chronic lung disease, and get access to the latest treatments not yet widely available - and be a part of finding a cure.
Interstitial lung disease is a blanket term covering a large group of pulmonary disorders that primarily involve the progressive scarring of your lung tissue. ILD affects the interstitium, which includes the walls of the air sacs of the lungs (alveoli) and the surrounding blood vessels.
Symptoms appear when the scar tissue impairs your ability to breathe and get enough oxygen to your vital organs. Once lung tissue scarring occurs, the damage is permanent.
In most cases, treatment for ILD focuses on slowing disease progression rather than curing the current amount of scarring you may have.
Some forms of ILD are idiopathic, which means their cause is unknown. These idiopathic forms include:
Sarcoidosis¹
Cryptogenic organizing pneumonia
Idiopathic interstitial pneumonia
Other types of ILDs are secondary to an identifiable cause. Typically, this is where you’ve had exposure to an occupational or environmental irritant, drug-induced lung toxicity, or radiation-induced lung injury. These include:
Hypersensitivity pneumonitis²
Sarcoidosis
Asbestosis³
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis⁴ (IPF), previously known as cryptogenic fibrosing alveolitis (CFA), is a severe lung condition that causes lung tissue thickening and scarring over time.
Despite being the most common type of idiopathic interstitial pneumonia, researchers still don’t know what causes this disease to develop. Scientists estimate that idiopathic pulmonary fibrosis affects 13-20 per 100,000 people worldwide.
The primary symptoms of ILD include:
Difficulty breathing
Fatigue
Dry cough
Loss of appetite
Depression
Weight loss
Rounding (clubbing) of the finger and toenails
If left untreated, ILD can lead to a variety of life-threatening complications, including:
Pulmonary hypertension⁵: Increased pressure in the arteries and veins of the lungs results in cardiovascular damage over time.
Right-sided heart failure⁶: Often due to pulmonary hypertension, increased stress on the heart can force the right ventricle to work harder, eventually leading to heart failure.
Respiratory failure⁷: During end-stage ILD, respiratory failure can occur due to large amounts of thick scar tissue.
While healthy lung tissue can heal and respond to injuries, people with ILD develop thick scar tissue in response to irritants. Some of the most common causes of ILD include:
Long-term exposure to irritants can cause ILD. These include:
Silica dust
Asbestos
Grain dust
Radiation
Cigarette smoke
Many drugs can have side effects that damage lung tissue, including:
Chemotherapy drugs like bleomycin⁸
Heart medications like amiodarone⁹ and propranolol
Antibiotics like nitrofurantoin¹⁰
Anti-inflammatory medicines like rituximab¹¹ (although rituximab is also an appropriate treatment¹²) and sulfasalazine¹³
Other medical conditions can lead to ILD. Autoimmune/connective tissue diseases cause lung issues, resulting in scar tissue. These conditions include:
Rheumatoid arthritis
Scleroderma
Sarcoidosis
Sjögren’s syndrome
In some cases, doctors don’t know what causes ILD.
The primary goal of ILD treatments is to slow the progression of scarring while improving your quality of life and comfort. Depending on your specific disease type and symptoms, your primary care provider will work with you to create a personalized treatment plan best suited to you.
Your doctor may prescribe medications to reduce the severity of symptoms, including:
If you have an autoimmune disorder, your doctor may prescribe corticosteroids¹⁴ to suppress your immune function to reduce scarring.
In some cases, you may develop acid reflux symptoms. Taking medications for acid reflux can reduce symptoms and enhance comfort.
Your doctor may prescribe nintedanib¹⁵ or pirfenidone¹⁶ to slow disease progression. These medications have significant side effects, so it’s best to speak with your provider to ensure that this treatment is right for you.
Your healthcare team may explore other treatment options to provide additional comfort after your diagnosis:
Oxygen therapy to make breathing easier and oxygenation better
Pulmonary rehabilitation through physical exercise and breathing techniques
Emotional and mental health support
Nutritional counseling
If you are not responding well to any of the above treatment options, your doctor may suggest lung transplant surgery. The risks and complications of this procedure can be substantial, so it is best to speak with your care provider to see if this option is right for you.
In addition to the above treatment options, a care provider may suggest a clinical trial for a new medication or treatment. You can get involved with Pulmonary Fibrosis Clinical Trials (PACT¹⁷) that offer cutting-edge research and treatments, access to leading specialists, extensive medical support, and more.
Because there are so many different types of ILD, a doctor may need to order various diagnostic tests to get to the root of your symptoms. These tests can include:
Blood work can detect antibodies, autoimmune markers, and signs of increased inflammation in the body that may have links to ILD.
A doctor can order computerized tomography (CT scans), chest x-rays, and echocardiograms to visualize your lungs and heart. These determine the size and location of scar tissue in the lungs.
Lung volumes, diffusing capacity, and spirometry tests can determine your current lung function, the severity of respiratory impairment, and breathing patterns.
A clinician can perform a washing sample (lavage) during a flexible bronchoscopy to obtain samples of cells and fluid from distal airways and alveoli.
A doctor can accurately diagnose pulmonary fibrosis by taking a lung tissue biopsy and sending it to pathology for examination.
Due to the nature of the disease, most patients only develop symptoms of ILD once significant scar tissue damage has already occurred. At this point, you will typically present with progressive dyspnea and exercise intolerance.
If you notice any changes in your breathing function, seek immediate medical care. Getting an early and accurate diagnosis is essential for living a longer life with ILD.
Interstitial lung disease (ILD) is a generalized term for various chronic and progressive pulmonary conditions that cause significant lung scarring. As a non-curable disease, current treatment for ILD focuses on slowing the progression of the damage. Maintaining regular visits with your primary care provider can increase your chance of early diagnosis.
Currently, there is no cure for ILD. Research and drug trials continue to push the boundaries of our current levels of care, and modern treatment options for ILD focus on slowing the progression of tissue scarring.
The symptoms and severity of ILD can vary from person to person. It also depends on the specific diagnosis. Researchers estimate that people diagnosed with idiopathic pulmonary fibrosis have a median life expectancy of 3-5 years¹⁸.
However, the actual range of survival is broad, with up to 25%¹⁹ of patients living upwards of ten years.
Scientists are conducting extensive research to better understand the long-term effects of COVID-19 on our lung health. One study²⁰ found that up to 24% of the group displayed radiographic changes to their lungs (signs of scarring) twelve months after recovering from a COVID-19 infection.
Furthermore, ongoing studies are establishing the exact risk of interstitial lung disease as a sequela (a condition that follows) of COVID-19²¹. Early results demonstrate interstitial lung damage, but whether this will progress to actual ILD is yet to be shown.
Chronic pulmonary obstructive disease (COPD) is an inflammatory disorder that causes narrowing and construction of your airway. ILD causes lung tissue to thicken and stiffen, making breathing more difficult over time.
During end-stage ILD, you will likely experience profound breathlessness, sometimes paired with depression, heartburn, and weight loss²². Once you reach this stage of the disease, you may require palliative comfort care to manage your symptoms.
Sources
Sarcoidosis (2022)
Hypersensitivity pneumonitis (2022)
Asbestosis (2022)
Cardiac manifestations of idiopathic pulmonary fibrosis (2016)
Rituximab-induced lung disease: a systematic literature review (2010)
Nintedanib in progressive fibrosing interstitial lung diseases (2019)
Find a trial | Lung Foundation Australia
Role of pirfenidone in the management of pulmonary fibrosis (2017)
Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium (2011)
Interstitial lung disease before and after COVID-19: a double threat? (2021)
Palliative care for patients with pulmonary fibrosis: symptom relief is essential (2018)
Other sources:
Idiopathic pulmonary fibrosis | Medline Plus
Symptom-based management of the idiopathic interstitial pneumonia (2016)
Depression in patients with idiopathic pulmonary fibrosis (2013)
The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients (2018)
Clubbing: An update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance (2005)
The genetic and environmental causes of pulmonary fibrosis (2012)
Patients with interstitial lung disease secondary to autoimmune diseases: How to recognize them? (2020)
We make it easy for you to participate in a clinical trial for Chronic lung disease, and get access to the latest treatments not yet widely available - and be a part of finding a cure.